HomeProductsBuilding BlocksHeterocyclic ScaffoldsQuinazolinesErlotinib
Chemical structure of CAS 183321-74-6

Erlotinib

In Stock•Starting at $10 for 250 mg•Purity ≥ 95%
CAS No.183321-74-6
MDL No.MFCD02089651
MFC22H23N3O4
MW393.40
InChI KeyAAKJLRGGTJKAMG-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
250 mg95%$10In Stock
1 g95%$12In Stock
5 g95%$34In Stock
25 g95%$140In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Erlotinib is a quinazoline compound with a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions. It functions as an antineoplastic agent, protein kinase inhibitor, and epidermal growth factor receptor antagonist. It belongs to quinazolines, terminal acetylenic compounds, aromatic ethers, and secondary amines.

CAS No.183321-74-6
Product NameErlotinib

Biological Targets

EGFR

Associated Conditions

neoplasm·colorectal cancer·triple-negative breast cancer·anaplastic oligodendroglioma·pancreatic neoplasm·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

The Journal of biological chemistry • Vol. 277, Issue 48 • 2002
PMID: 12196540DOI: 10.1074/jbc.M207135200

[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].

Nihon Geka Gakkai zasshi • Vol. 103, Issue 2 • 2002
PMID: 11904986

Targeting epidermal growth factor receptor in lung cancer.

Current oncology reports • Vol. 4, Issue 4 • 2002
PMID: 12044241DOI: 10.1007/s11912-002-0007-1

The epidermal growth factor receptor: a new target for anticancer therapy.

Current problems in cancer • Vol. 26, Issue 3 • 2002
PMID: 12085086DOI: 10.1067/mcn.2002.125874

Documentation

Similar Products